Filana Therapeutics, Inc. (FLNA) News
Follow Filana Therapeutics, Inc. (FLNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Filana Therapeutics Officer Acquires Shares Worth $55,924.50
EQUITY | Nov 18, 2026, 09:07 PM UTC
L
Filana Therapeutics 3Q 2026: EPS ($0.22) — 10-Q Summary
Filana Therapeutics reported a narrower quarterly net loss year over year, as lower research and development and general and administrative expenses more than offset reduced interest income. The company has not generated
EARNINGS | Nov 05, 2026, 09:18 PM UTC
M
Filana Therapeutics Reports Q3 2026 Results and Business Update
The company said patient screening in its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2.
EQUITY | Nov 05, 2026, 01:15 PM UTC
M
FDA lifts clinical hold on Filana’s simufilam for TSC-related epilepsy
TradingView News reports the FDA lifted the clinical hold on Filana’s simufilam for TSC-related epilepsy.
EQUITY | Sep 22, 2026, 12:45 PM UTC
M
FDA lifts clinical hold on simufilam IND; Phase 2a in TSC epilepsy
Filana Therapeutics said the FDA lifted the clinical hold on its IND for simufilam, enabling a planned Phase 2a study in TSC-related epilepsy, with screening expected to begin by Q1 2027.
REGULATION | Sep 22, 2026, 12:04 PM UTC
L
FLNA - Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
FLNA - Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
EQUITY | Aug 12, 2026, 06:21 PM UTC
L
FLNA - Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
FLNA - Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
EARNINGS | Jul 29, 2026, 12:00 PM UTC